Last reviewed · How we verify

GSK Biologicals' 208136, new formulation

GlaxoSmithKline · Phase 2 active Biologic

GSK Biologicals' 208136, new formulation is a PD-1 inhibitor Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

This drug targets the PD-1 receptor to modulate the immune response.

This drug targets the PD-1 receptor to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

At a glance

Generic nameGSK Biologicals' 208136, new formulation
SponsorGlaxoSmithKline
Drug classPD-1 inhibitor
TargetPD-1
ModalityBiologic
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

By binding to PD-1, it prevents the interaction with its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation. This leads to enhanced anti-tumor immune responses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK Biologicals' 208136, new formulation

What is GSK Biologicals' 208136, new formulation?

GSK Biologicals' 208136, new formulation is a PD-1 inhibitor drug developed by GlaxoSmithKline, indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

How does GSK Biologicals' 208136, new formulation work?

This drug targets the PD-1 receptor to modulate the immune response.

What is GSK Biologicals' 208136, new formulation used for?

GSK Biologicals' 208136, new formulation is indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

Who makes GSK Biologicals' 208136, new formulation?

GSK Biologicals' 208136, new formulation is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is GSK Biologicals' 208136, new formulation in?

GSK Biologicals' 208136, new formulation belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is GSK Biologicals' 208136, new formulation in?

GSK Biologicals' 208136, new formulation is in Phase 2.

What are the side effects of GSK Biologicals' 208136, new formulation?

Common side effects of GSK Biologicals' 208136, new formulation include Pneumonitis, Hypothyroidism, Diarrhea, Fatigue, Nausea, Rash.

What does GSK Biologicals' 208136, new formulation target?

GSK Biologicals' 208136, new formulation targets PD-1 and is a PD-1 inhibitor.

Related